Skip to main content
. Author manuscript; available in PMC: 2021 Mar 30.
Published in final edited form as: Circ Heart Fail. 2020 Nov 9;13(12):e007879. doi: 10.1161/CIRCHEARTFAILURE.120.007879

Table 3. Treatment effect according to duration of heart failure (dapagliflozin vs placebo hazard ratio or difference and 95% confidence interval).

Overall HR (95% CI) or Difference HF ≥2 months-1 year HR (95% CI) or Difference HF >1-2 years HR (95% CI) or Difference HF >2-5 years HR (95% CI) or Difference HF >5 years HR (95% CI) or Difference P for interaction
Number of patients 4744 1098 686 1105 1855 -
Worsening HF or cardiovascular death 0.74
(0.65-0.85)		 0.86
(0.63-1.18)		 0.95
(0.64-1.42)		 0.74
(0.57-0.96)		 0.64
(0.53-0.78)		 0.26
Hospitalization or urgent visit for HF 0.70
(0.59-0.83)		 0.76
(0.49-1.17)		 0.92
(0.56-1.50)		 0.64
(0.46-0.90)		 0.64
(0.51-0.82)		 0.52
HF hospitalization 0.70
(0.59-0.83)		 0.71
(0.45-1.11)		 0.92
(0.56-1.50)		 0.65
(0.46-0.91)		 0.66
(0.52-0.84)		 0.61
Urgent HF visit 0.43
(0.20-0.90)		 1.04
(0.21-5.16)		 1.16
(0.07-18.75)		 0.25
(0.05-1.23)		 0.31
(0.10-0.97)		 0.49
Cardiovascular death 0.82
(0.69-0.98)		 0.96
(0.63-1.45)		 0.79
(0.45-1.36)		 0.94
(0.67-1.33)		 0.72
(0.55-0.93)		 0.54
Cardiovascular death or HF hospitalization 0.75
(0.65-0.85)		 0.84
(0.61-1.16)		 0.96
(0.64-1.42)		 0.75
(0.58-0.97)		 0.65
(0.53-0.80)		 0.33
Total number of HF hospitalizations* and cardiovascular deaths 0.75
(0.65-0.88)		 0.79
(0.55-1.13)		 0.80
(0.51-1.28)		 0.81
(0.61-1.08)		 0.68
(0.55-0.85)		 0.77
All-cause mortality 0.83
(0.71-0.97)		 0.97
(0.66-1.40)		 0.80
(0.48-1.33)		 0.92
(0.68-1.26)		 0.72
(0.57-0.92)		 0.52
Significant worsening in KCCQ-TSS† (≥5) at 8 months‡ 0.96
(0.91-1.01)		 0.91
(0.79-1.04)		 0.85
(0.71-1.02)		 0.82
(0.72-0.95)		 0.79
(0.72-0.88)		 0.11
Significant improvement in KCCQ-TSS† (≥5) at 8 months‡ 1.01
(0.96-1.06)		 1.16
(1.02-1.31)		 1.17
(1.00-1.38)		 1.09
(0.96-1.25)		 1.19
(1.08-1.31)		 0.79
Change in KCCQ-TSS§ at 8 months 2.81±0.61 3.28±1.27 1.01±1.59 0.81±1.31 4.47±0.95 0.08
*

Effect of dapagliflozin on total HF hospitalizations was assessed using the LWYY model and is shown as rate ratios (RRs).

†

Scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) range from 0 to 100 (higher scores indicating fewer symptoms and physical limitations associated with heart failure).

‡

Effect of dapagliflozin on significant improvement or worsening in KCCQ total symptom score (≥5) at 8 months is shown as odds ratios (ORs).

§

Treatment difference in mean change in KCCQ scores ± standard error (SE).